Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer
Phaedra C Ghazi, Kayla T O'Toole, Sanjana Srinivas Boggaram, Michael T Scherzer, Mark R Silvis, Yun Zhang, Madhumita Bogdan, Bryan D Smith, Guillermina Lozano, Daniel L Flynn, Eric L Snyder, Conan G Kinsey, Martin McMahon
This study shows that combining ULK1/2 inhibition with KRASG12C inhibitors reduces lung cancer growth in preclinical models.
bioRxiv · Feb 6, 2024Cancer Biology